MXPA05007519A - Nuevos derivados de la purina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion. - Google Patents

Nuevos derivados de la purina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.

Info

Publication number
MXPA05007519A
MXPA05007519A MXPA05007519A MXPA05007519A MXPA05007519A MX PA05007519 A MXPA05007519 A MX PA05007519A MX PA05007519 A MXPA05007519 A MX PA05007519A MX PA05007519 A MXPA05007519 A MX PA05007519A MX PA05007519 A MXPA05007519 A MX PA05007519A
Authority
MX
Mexico
Prior art keywords
novel
medicaments
nr4r5
alkyl
preparation
Prior art date
Application number
MXPA05007519A
Other languages
English (en)
Inventor
Haesslein Jean-Luc
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MXPA05007519A publication Critical patent/MXPA05007519A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion tiene como objeto los productos de formula (I), en la que: Y representa N, O, S, CHR3 o =CR3, indicando la linea de puntos un enlace sencillo o doble; R y R1, representan, en particular, H, halogeno, OH, alquilo, alcoxi, ciano, NO2, NR4R5, trifluorometilo, trifluorometoxi, arilo, heteroarilo, -S(O)n-NR4R5, donde n representa de 0 a 2, acilo, -NH-CO-alquilo o -NH-CO-NH-fenilo, R3 representa H, halogeno, alquilo, ciano, NO2, NR4R5, trifluorometilo o arilo; R2 representa R4, OR4, SR4 o NR4R5; y R4 representa H, alquilo, cicloalquilo o arilo. De acuerdo con la invencion, R4 y R5 se seleccionan entre los valores de R4, o R4 y R5, junto con N, forman un radical heterociclico que puede contener N, O y S, estando todos los mencionados radicales opcionalmente sustituidos. Ademas, los productos anteriormente mencionados toman todas las formas isomeras y las sales para uso como medicamentos.
MXPA05007519A 2003-02-18 2004-02-13 Nuevos derivados de la purina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion. MXPA05007519A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301915A FR2851248B1 (fr) 2003-02-18 2003-02-18 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
PCT/FR2004/000330 WO2004073595A2 (fr) 2003-02-18 2004-02-13 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation

Publications (1)

Publication Number Publication Date
MXPA05007519A true MXPA05007519A (es) 2005-09-21

Family

ID=32749627

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007519A MXPA05007519A (es) 2003-02-18 2004-02-13 Nuevos derivados de la purina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.

Country Status (11)

Country Link
EP (1) EP1597258B1 (es)
JP (1) JP2006517955A (es)
AT (1) ATE413401T1 (es)
AU (1) AU2004212733B2 (es)
BR (1) BRPI0407578A (es)
CA (1) CA2515610A1 (es)
DE (1) DE602004017580D1 (es)
FR (1) FR2851248B1 (es)
IL (1) IL170318A (es)
MX (1) MXPA05007519A (es)
WO (1) WO2004073595A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
WO2006090261A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
GB0519245D0 (en) * 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
AU2007337895C1 (en) 2006-12-22 2014-07-31 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
CA2674875A1 (en) * 2007-01-23 2008-07-31 Palau Pharma, S.A. Purine derivatives
US8404674B2 (en) 2007-03-07 2013-03-26 Boehringer Ingelheim International Gmbh Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
BRPI0817503B8 (pt) * 2007-10-05 2021-05-25 Sstarbio Pte Ltd derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
CA2730271A1 (en) * 2008-07-07 2010-01-14 Xcovery Holding Company Llc Pi3k isoform selective inhibitors
MX359989B (es) * 2012-02-17 2018-10-18 Siga Tech Inc Fármacos antivirales para el tratamiento de la infección por arenavirus.
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
RU2760305C1 (ru) * 2021-04-26 2021-11-23 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН) 4-[(Пурин-6-ил)аминополиметиленкарбонил]-производные 3,4-дигидро-3-метил-7,8-дифтор-2H-[1,4]бензоксазина, обладающие противоопухолевой активностью

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012718A1 (en) * 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
SK72996A3 (en) * 1995-06-07 1997-04-09 Pfizer Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base
GEP20033092B (en) * 1999-02-01 2003-10-27 Cv Therapeutics Inc Us Purine Inhibitors of Cyclin Dependent Kinase 2 and Ik-Aa
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
ATE426603T1 (de) * 2000-10-31 2009-04-15 Aventis Pharma Inc Acyl- und sulfonylderivative 6,9- disubstitutierter 2-(trans-1,4-diaminocyclohexyl)-purine und ihre verwendung als antiproliferative mittel
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Also Published As

Publication number Publication date
DE602004017580D1 (de) 2008-12-18
EP1597258A2 (fr) 2005-11-23
JP2006517955A (ja) 2006-08-03
IL170318A (en) 2011-02-28
WO2004073595A2 (fr) 2004-09-02
AU2004212733B2 (en) 2009-12-24
AU2004212733A1 (en) 2004-09-02
BRPI0407578A (pt) 2006-02-14
FR2851248B1 (fr) 2005-04-08
FR2851248A1 (fr) 2004-08-20
CA2515610A1 (fr) 2004-09-02
EP1597258B1 (fr) 2008-11-05
WO2004073595A3 (fr) 2005-01-06
ATE413401T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
HRP20020926B1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
MXPA05007519A (es) Nuevos derivados de la purina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.
JO2935B1 (en) 6- Tertiary azulo pyridazine sulfanil benzothiazole and benzimidazole derivatives, method of preparation, use as pharmaceutical products, pharmaceutical compositions and new use in particular as met inhibitors (methionine)
WO2008081096A3 (fr) Derives quinolinyliques, leur procede de preparation. les compositions pharmaceutiques qui les contiennent et leur utilisation comme agents hypoglycemiants et hypoli pemiants
WO2012033858A3 (en) Benzoxaborole derivatives for treating bacterial infections
BR112013010552A2 (pt) derivado de piridina e agente medicinal
IL177280A (en) Monohydrate crystal of 2-aminothiazole-5-aromatic carboxamide, process for its preparation, its pharmaceutical composition and its use in the preparation of medicine
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
NO20051051L (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler
TW200738684A (en) Novel sulfated cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
MX2007003872A (es) Nuevos derivados bis-azaindolicos, preparacion y su uso farmaceutico de los mismos como inhibidores de cinasas.
AR044825A1 (es) Derivados de 5,6-diaril-pirazinas-2-carboxamida y -2-sulfonamidas -3-sustituidas como moduladores de cb1
BRPI0507944A (pt) composição farmacêutica
WO2010007316A3 (fr) NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
WO2006117211A3 (en) Urea derivatives methods for their manufacture and uses thereof
HK1089746A1 (en) Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof
AR052898A1 (es) Derivados de la n-[(4,5-difenil -2-tienil) metil] amina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para enfermedades mediadas por los receptores canabinoides cb1
WO2010007318A3 (fr) NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
BRPI0416039A (pt) derivados de tiazol e pirazol como inibidores de flt-3 cinase
WO2004096792A3 (fr) Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
ATE482933T1 (de) Sulfopyrrolderivate
WO2008046982A3 (fr) Nouveaux derives imidazolones, leur preparation a titre de medicaments, compositions pharmaceutiques, utilisation comme inhibiteurs de proteines kinases notamment cdc7
TW200745048A (en) Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors
MX2009004625A (es) Derivados de 3-amino-pirazol-4-carboxamida utiles como inhibidores de proteina cinasas.

Legal Events

Date Code Title Description
FG Grant or registration